Atrial Flow Regulator Helps Manage Heart Failure
By HospiMedica International staff writers Posted on 16 Sep 2019 |
Image: A novel blood flow regulator decompresses the heart (Photo courtesy of Occlutech).
A next generation implantable shunt device treats heart failure (HF) or pulmonary hypertension (PH) symptoms by decompressing abnormal intra-atrial pressure.
The Occlutech (Schaffhausen, Switzerland) atrial flow regulator (AFR) HF Device is a double-disc shaped shunt placed in the septum between the left and right atriums, via a minimally invasive balloon atrial septostomy (BAS) procedure, in order to create a restrictive atrial septal opening. Made of nickel-titanium (Nitinol), the AFR is intended to maintain a permanent interatrial fenestration of varying diameters (6-10 mm) secured by two discs. Depending on the indication (HF or PH), the shunt allows for the controlled flow of blood between the atria of the heart.
By maintaining the predetermined diameter shunt open in the intra-atrial septum, cardiac pressure is substantially reduced, resulting in a decompression of the heart chambers which leads to reduced HF and PH symptoms, and as a result to an improved exercise tolerance and to better quality of life (QOL). The AFR HF Device is manufactured in different sizes, allowing for a unique, patient-oriented, and individualized treatment. The Occlutech AFR Device has received the European Union CE mark of approval.
“With CE mark approval of the Occlutech AFR we are taking another big step towards becoming a multi-franchise congenital and structural heart disease therapy provider,” said Sabine Bois, Co-CEO of Occlutech. “The Occlutech AFR with its efficacy, versatility, convenience, and safety has true potential to revolutionize the way heart failure patients are treated.”
Unlike systemic blood pressure, pulmonary blood pressure reflects the pressure the heart exerts to pump blood from the right ventricle, which receives the oxygen-depleted blood, into the pulmonary arteries, and on to the left atrium. Normal pulmonary artery pressure is 8-20 mm Hg at rest (much lower than systemic blood pressure); if the pressure in the pulmonary artery is greater than 25 mm Hg at rest or 30 mmHg during physical activity, it is abnormally high and is called PH.
Related Links:
Occlutech
The Occlutech (Schaffhausen, Switzerland) atrial flow regulator (AFR) HF Device is a double-disc shaped shunt placed in the septum between the left and right atriums, via a minimally invasive balloon atrial septostomy (BAS) procedure, in order to create a restrictive atrial septal opening. Made of nickel-titanium (Nitinol), the AFR is intended to maintain a permanent interatrial fenestration of varying diameters (6-10 mm) secured by two discs. Depending on the indication (HF or PH), the shunt allows for the controlled flow of blood between the atria of the heart.
By maintaining the predetermined diameter shunt open in the intra-atrial septum, cardiac pressure is substantially reduced, resulting in a decompression of the heart chambers which leads to reduced HF and PH symptoms, and as a result to an improved exercise tolerance and to better quality of life (QOL). The AFR HF Device is manufactured in different sizes, allowing for a unique, patient-oriented, and individualized treatment. The Occlutech AFR Device has received the European Union CE mark of approval.
“With CE mark approval of the Occlutech AFR we are taking another big step towards becoming a multi-franchise congenital and structural heart disease therapy provider,” said Sabine Bois, Co-CEO of Occlutech. “The Occlutech AFR with its efficacy, versatility, convenience, and safety has true potential to revolutionize the way heart failure patients are treated.”
Unlike systemic blood pressure, pulmonary blood pressure reflects the pressure the heart exerts to pump blood from the right ventricle, which receives the oxygen-depleted blood, into the pulmonary arteries, and on to the left atrium. Normal pulmonary artery pressure is 8-20 mm Hg at rest (much lower than systemic blood pressure); if the pressure in the pulmonary artery is greater than 25 mm Hg at rest or 30 mmHg during physical activity, it is abnormally high and is called PH.
Related Links:
Occlutech
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration